Sign in
BRNS Stock Price, Chart, Stats & News
Barinthus Biotherapeutics plc
Save
Barinthus Biotherapeutics plc (BRNS) does not currently pay a dividend.
23.07M
Market cap
–
Current P/E
–
Forward P/E
BRNS chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 0.42% |
ROA | -67.67% |
ROE | -70.57% |
D/E | 0.15x |
Interest coverage ratio | -1063.03x |
BRNS valuation
P/E | – |
P/S | – |
P/B | 0.30x |
P/CF | -0.47x |
P/FCF | -0.47x |
P/OCF | -0.47x |
PEG | -0.03x |
EV multiple | -1.39x |
About
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical firm, is dedicated to pioneering innovative T-cell immunotherapies. These cutting-edge treatments are engineered to harness the body's own immune system to effectively combat chronic infectious diseases, autoimmune disorders, and various cancers. The company is actively progressing a robust portfolio of experimental medicines spanning diverse medical fields.
Similar securities
Based on sector and market capitalization
Report issue